Drug Trial Radar · NCT02018861
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
Last checked: Nov 19, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
88
Actual
Start
Sep 22, 2016
Primary completion
Apr 12, 2021
Study completion Apr 12, 2021
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Dec 23, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open-label, dose-escalation study in subjects with previously treated B-cell malignancies to find maximum tolerated dose (MTD) or pharmacologic active dose of a PI3Kδ inhibitor, parsaclisib, as monotherapy and in combination with: itacitinib (INCB039110), a JAK1 inhibitor; rituximab; and rituximab, ifosfamide, carboplatin, and etoposide. Parsaclisib inhibits PI3Kδ, a protein involved in growth and survival of B-cell cancer cells.
Conditions
- B-Cell Malignancies
Interventions
ParsaclisibDrug
ItacitinibDrug
RituximabDrug
IfosfamideDrug
CarboplatinDrug
EtoposideDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Up to approximately 53 months (4.4 years)
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama At Birmingham Comprehensive Cancer Center
Birmingham, Alabama
University of Michigan Cancer Center
Ann Arbor, Michigan
Karmanos Cancer Institute
Detroit, Michigan
Nyu Langone Laura and Isaac Perlmutter Cancer Center
New York, New York
University Hospitals Case Medical Center
Cleveland, Ohio
Greenville Health System Cancer Institute
Greenville, South Carolina
Baylor Charles A. Sammons Cancer Center
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.